CSI Market
Sign In | Register

Aslan Pharmaceuticals Limited (ASLN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ASLN Annual Cash Flow →
Examining cash flow movements between Aslan Pharmaceuticals Limited and Dec 31 2022 reveals how Dec 31 2023 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		0 0 0 (Dec 31 2022)
Operating Activities
Income-44.09
Depreciation & amortization0.34
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets1.10
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.20
Adjustment For Loss On Lease Modification-
Adjustments For Increase Decrease In Prepayments-
Adjustments For Increase Decrease In Trade Account Payable-
Net Gain Losses On Changes In Fair Value Of Financial Assets And Liabilities Routed Through Profit Or Loss-
Adjustments For Finance Costs-
Adjustments For Interest Income-
Adjustments For Sharebased Payments-
Gain Loss On Lease Termination-
Income Taxes Paid Refund Classified As Operating Activities-
Income taxes0.00
Purchase Of Intangible Assets Classified As Investing Activities0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Other Adjustments To Reconcile Profit Loss0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-40.07
Discontinued operations0.00
Net Cash flow from Operating Activities-46.64
Investing Activities
Capital Expenditures0.01
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.28
Discontinued operations0.00
Net Cash Flow from Investing Activities0.27
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net38.69
Proceeds From Issue Of Preference Shares-
Proceeds From Issuing Shares-
Payments For Share Issue Costs-
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.72
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-46.63
Total Cash Flow56.90
4 historic quarters locked

Sign in to unlock the full Aslan Pharmaceuticals Limited cash flow history.

Sign In Create Free Account

About Aslan Pharmaceuticals Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-043860

Figures are derived from filed reports and may be restated. Historical data is subject to revision.